Orthofix Medical (OFIX) Cash & Equivalents (2009 - 2026)

Orthofix Medical has disclosed Cash & Equivalents across 18 years of filings, most recently posting $120.3 million for Q1 2026.

• Quarterly Cash & Equivalents rose 107.54% year-over-year to $120.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120.3 million (up 107.54% YoY) and the FY2025 annual result came in at $82.0 million, down 1.46% from the prior year.
• Cash & Equivalents improved to $120.3 million in Q1 2026, from $82.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $120.3 million in Q1 2026 and troughed at $26.4 million in Q2 2024.
• A 5-year average of $55.5 million and a median of $51.7 million in 2022 frame the typical range for Cash & Equivalents.
• Biggest YoY gain for Cash & Equivalents was 151.42% in 2024; the steepest drop was 46.04% in 2024.
• Tracing OFIX's Cash & Equivalents over 5 years: stood at $50.7 million in 2022, then sank by 34.7% to $33.1 million in 2023, then soared by 151.42% to $83.2 million in 2024, then declined by 1.46% to $82.0 million in 2025, then surged by 46.64% to $120.3 million in 2026.
• Business Quant data shows OFIX's Cash & Equivalents at $120.3 million in Q1 2026, $82.0 million in Q4 2025, and $62.9 million in Q3 2025.